Survey Study for Velaglucerase Alfa (VPRIV) in Japan

Takeda

Status: Completed

Conditions: Gaucher Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT03625882

SHP-GCB-401

Details and patient eligibility

About

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Enrollment: 77 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female participants with a confirmed diagnosis of Gaucher disease
• Participants who are either naïve to treatment or participants that have been treated with another therapeutic agent for Gaucher disease
• Participants who start VPRIV treatment or transition from VPRIV clinical studies during the enrollment period

Exclusion criteria

Trial design

77 participants in 1 patient group

Gaucher Disease Participants Treated With VPRIV

Description:

Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.